Catalyst Biosciences Inc (NASDAQ: CBIO) stock enjoyed a major increase of 12.5% on 7/16/24. The shares closed at $15.71. Trading volume in this advance was normal. The stock has been weak relative to the market over the last nine months but has risen 29.2% during the last week.
Current PriceTarget Research Rating
CBIO is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment